Message #5 From:
NewsBot Date: July 10, 2006 04:00:00 AM
IFMX News SUNRx to Market and Sell InforMedix's Med-eMonitor System; ''Smart Pillbox'' to Be Offered to Labor Unions and Self-Insured Employers
ROCKVILLE, Md.--(BUSINESS WIRE)--July 10, 2006--InforMedix Holdings, Inc. (OTCBB:IFMX), creating a new technology platform that improves medication adherence and enables patients to manage chronic illnesses at home, today announced its Med-eMonitor System (TM) will be marketed and sold by SUNRx.
Based in Cherry Hill, NJ, privately held SUNRx is a rapidly-growing pharmacy benefits administration company ranked #1 in the Philadelphia area's 100 fastest growing companies by the Wharton School, and ranked 19th fastest growing company in the United States by Entrepreneur Magazine. SUNRx has experienced growth exceeding 2000% per year since its founding in 2002.
Through use of its proprietary software, national retail pharmacy network of over 60,000 pharmacies, its strategic mail order pharmacy distribution, and specialty pharmacy partnerships, SUNRx provides prescription benefit administrative services to maximize the safe and efficient administration of medications while reducing prescription drug costs for clients that include individuals, Managed Care Organizations, self-insured employers, insurance companies, unions, Medicaid and Medicare managed care plans, Federal Employees Health Benefit Programs and other Federal, state and local governmental entities.
According to SUNRx's CEO, Gerard Ferro, "We are proud to make InforMedix's breakthrough medication and care plan adherence system available to our clients, and through them to patients with chronic illnesses they are managing at home. SUNRx is very selective in its partnering relationships, and after spending more than a year getting to know InforMedix and the Med-eMonitor System we think there are substantial benefits to our customers both in terms of improved patient outcomes and lower costs."
The Med-eMonitor(TM) System includes a device that goes home with the patient. The device alerts the patient when it is time to take their medications. It reminds them how to properly take their medications. It also provides important educational information about their medications, disease state and overall plan of care. The data from the device is transmitted daily to a secure Internet site. This allows the care givers (Physicians, Pharmacists, Nurses and family members) to monitor medication and care plan adherence every day. The system will also alert the care giver, through an e-mail, text message, fax, or page if the data on the patient indicates poor adherence or declining health.
According to Bruce A. Kehr, M.D., chairman and Chief Executive Officer of InforMedix, "We are very proud SUNRx selected InforMedix as its medication adherence partner. SUNRx has a blistering growth rate as evidenced by the awards that they have won from Entrepreneur Magazine, PriceWaterhouseCoopers, the Wharton School, the Philadelphia Business Journal, and the Entrepreneurs Forum of Greater Philadelphia. They also have a superb reputation in the field for trust and integrity. We believe they will be a superb channel partner and that the relationship will result in meaningful sales over the next six to twelve months."
About SUNRx
SUNRx was incorporated in January 2002 and since that time has dedicated its efforts to developing the Nation's first proprietary Prescription Benefit Administrative Advocate service designed to reduce spiraling prescription plan costs. As the first Pharmacy Benefit Administrator in the United States, with over 60 years of management experience in healthcare, pharmaceutical and prescription plan design, implementations and service, SUNRx advocates true Transparent Prescription Plan Administration. The Company offers industry revolutionizing point of sale technology, Maintenance Medication programs at retail and mail order and incentivized generic offerings that are all designed to maximize safety, efficacy and contain costs. SUNRx will continue to bring unprecedented discounts and savings to the Prescription Benefit market, and help clients meet their prescription healthcare goals by providing expert advice and delivering innovative, customized plans. SUNRx works with their clients through a true partnership built upon Integrity and Trust. For more information, please visit www.SUNRx.com.
About InforMedix
InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication and care plan adherence, clinical response, and drug safety. The Med-eMonitor is specifically designed to improve patient medication compliance and care plan adherence in disease management and clinical drug trials programs. In a recent program for diabetes patients, the Med-eMonitor System improved mean medication adherence rates to over 92% compared to a baseline medication adherence rate of 40%, and also reduced Hemoglobin A1c (HbA1c) levels by an average of 18.5% in a 3 month period (p value less than .002). The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued (13 active) patents, and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB:IFMX), visit our website at www.informedix.com.
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These forward-looking statements include SUNRx "think(s) there are substantial benefits to our customers both in terms of improved patient outcomes and lower costs." References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
